Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC
NCT07720921Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in upper tract urothelial carcinoma (UTUC), sponsored by Peking University First Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07720921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720921.